Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review
Authors:
- Roxana Manuela FericeanRFRoxana Manuela Fericean
- Cristian OanceaCOCristian Oancea
- Akash Reddy ReddyreddyARAkash Reddy Reddyreddy
- Ovidiu RoscaOROvidiu Rosca
- Felix BratosinFelix Bratosin
- Vlad BloancaVBVlad Bloanca
- Cosmin CituCCCosmin Citu
- Satish AlambaramSASatish Alambaram
- Neeharika Gayatri VasamsettiNVNeeharika Gayatri Vasamsetti
- Catalin DumitruCDCatalin Dumitru
Open Access
- 25 January 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (3) , 2150
Abstract
The Omicron (B.1.1.529) variant of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) had an increased rate of spreading among the general population. Although this virus mutation resulted in milder symptoms, those on the vulnerable side of the population are still in danger of developing severe symptoms. Thus, this systematic review focused on identifying the clinical outcomes of older age patients (>65) that are hospitalized with the SARS-CoV-2 Omicron variant. The research was conducted using four electronic databases (PubMed, Scopus, Web of Science, and ProQuest Central), with a search query in December 2022 that comprised the duration of the COVID-19 pandemic. The inclusion criteria comprised (1) a population of patients older than 65 years, (2) a history of hospitalization for SARS-CoV-2 infection, and (3) infection with Omicron B.1.1.529 variant. The initial search generated 295 articles, out of which six were included in the systematic review, and a total of 7398 patients. The main findings were that when looking at the elderly population, the mortality and hospitalization rates remained high. This is because older people are more vulnerable and have more comorbidities that interfere with the virus’s progress. However, there is inconsistency in mortality rates, since the data reported by the included studies had different selection criteria based on the severity of the COVID-19 infection. Although no statistically significant differences were found between the unvaccinated and vaccinated groups, patients who got booster doses of vaccination had a lower likelihood of developing severe symptoms, serving as a protective factor for this population.Keywords
This publication has 37 references indexed in Scilit:
- Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021–2022Viruses, 2022
- Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysisBMJ, 2022
- Hospitalized patients with severe COVID-19 during the Omicron wave in Israel - benefits of a fourth vaccine dosemedRxiv, 2022
- Retrospective cohort study of COVID-19 in patients of the Brazilian public health system with SARS-COV-2 Omicron variant infectionResearch Square, 2022
- Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022Eurosurveillance, 2022
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regressionThe Lancet, 2022
- mRNA Vaccines in the COVID-19 Pandemic and BeyondAnnual Review of Medicine, 2022
- New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current KnowledgeClinical Pathology, 2022
- Why are some coronavirus variants more infectious?Journal of Biosciences, 2021
- Quality assessment tools used in systematic reviews of in vitro studies: A systematic reviewBMC Medical Research Methodology, 2021